• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.

作者信息

Heng Wei, You Chuanyun, Shangli Cai, Chuang Qi, Mingzhe Xiao

机构信息

The Department of respiratory medicine, the First Affiliated Hospital of Soochow University, China.

The Department of respiratory medicine, the First Affiliated Hospital of Soochow University, China.

出版信息

Lung Cancer. 2019 Oct;136:153-155. doi: 10.1016/j.lungcan.2019.07.030. Epub 2019 Jul 31.

DOI:10.1016/j.lungcan.2019.07.030
PMID:31422893
Abstract
摘要

相似文献

1
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations.一名携带EGFR L858R和Q787k突变的肺腺癌患者对埃克替尼的原发性耐药
Lung Cancer. 2019 Oct;136:153-155. doi: 10.1016/j.lungcan.2019.07.030. Epub 2019 Jul 31.
2
Lung adenocarcinoma patient with EGFR 19 exon insert mutation and its response to icotinib.表皮生长因子受体19外显子插入突变的肺腺癌患者及其对埃克替尼的反应。
Lung Cancer. 2018 Jul;121:101-104. doi: 10.1016/j.lungcan.2018.04.019. Epub 2018 Apr 24.
3
Combination of icotinib and chemotherapy as first-line treatment for advanced lung adenocarcinoma in patients with sensitive EGFR mutations: A randomized controlled study.厄洛替尼联合化疗对比单纯化疗一线治疗表皮生长因子受体敏感突变晚期肺腺癌的随机对照研究
Lung Cancer. 2019 Jul;133:23-31. doi: 10.1016/j.lungcan.2019.05.008. Epub 2019 May 7.
4
Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report.阿法替尼治疗后获得 EGFR Leu792H 突变的转移性肺腺癌对伊可替尼的阳性反应：一例报告。
BMC Cancer. 2019 Feb 8;19(1):131. doi: 10.1186/s12885-019-5352-7.
5
Clinical characterization of icotinib-induced chemoresistance in erlotinib-treated lung adenocarcinoma patient with EGFR mutations: A case report.埃克替尼诱导的对厄洛替尼治疗的表皮生长因子受体（EGFR）突变肺腺癌患者化疗耐药的临床特征：病例报告
Medicine (Baltimore). 2019 May;98(18):e15489. doi: 10.1097/MD.0000000000015489.
6
Effectiveness of EGFR-TKIs in a Patient with Lung Adenocarcinoma Harboring an Fusion.携带融合的肺腺癌患者中 EGFR-TKIs 的疗效。
Oncologist. 2019 Aug;24(8):1027-1030. doi: 10.1634/theoncologist.2018-0732. Epub 2019 May 7.
7
Icotinib, an effective treatment option for patients with lung adenocarcinoma harboring compound EGFR L858R and A871G mutation.厄洛替尼是一种有效的治疗方法，适用于携带 EGFR L858R 和 A871G 复合突变的肺腺癌患者。
Invest New Drugs. 2021 Oct;39(5):1419-1421. doi: 10.1007/s10637-021-01108-3. Epub 2021 Apr 9.
8
Efficacy of icotinib in advanced lung squamous cell carcinoma.伊可替尼治疗晚期肺鳞癌的疗效。
Cancer Med. 2018 Sep;7(9):4456-4466. doi: 10.1002/cam4.1736. Epub 2018 Aug 14.
9
Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines.金雀异黄素，一种特异性 CK2 抑制剂，能够降低人肺腺癌细胞株对伊可替尼的耐药性。
Int J Mol Med. 2019 Aug;44(2):437-446. doi: 10.3892/ijmm.2019.4220. Epub 2019 May 30.
10
Real-world efficacy and potential mechanism of resistance of icotinib in Asian advanced non-small cell lung cancer with EGFR uncommon mutations: A multi-center study.真实世界中埃克替尼治疗亚洲晚期非小细胞肺癌伴 EGFR 罕见突变患者的疗效及耐药潜在机制：一项多中心研究。
Cancer Med. 2020 Jan;9(1):12-18. doi: 10.1002/cam4.2652. Epub 2019 Nov 6.

引用本文的文献

1
Mitochondria-associated non-coding RNAs and their impact on drug resistance.线粒体相关非编码RNA及其对耐药性的影响。
Front Pharmacol. 2025 Feb 26;16:1472804. doi: 10.3389/fphar.2025.1472804. eCollection 2025.
2
A multiple detection method for distinguishing gene mutations based on melting curves of extended quenching probes.一种基于延长淬灭探针熔解曲线区分基因突变的多重检测方法。
Heliyon. 2022 Nov 26;8(11):e11856. doi: 10.1016/j.heliyon.2022.e11856. eCollection 2022 Nov.